{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:47Z","timestamp":1793896487173,"version":"4.8.0"},"reference-count":56,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Mutations in the isocitrate dehydrogenase (IDH) genes, IDH1 and IDH2, are recurrently found in patients with myeloid neoplasms (MN) and clinically targeted by small-molecule inhibitors. We aimed to comprehensively study the genetic pattern and underlying clonal architecture in a large cohort of 12\u2009071 patients (acute myeloid leukemia [AML], n = 4113; myelodysplastic neoplasms [MDS], n = 6316; or chronic myelomonocytic leukemia [CMML], n = 1642). IDH mutations were found in 28% of patients with AML (IDH1, 10%; IDH2, 18%), 6.3% of patients with MDS (IDH1, 1.8%; IDH2, 4.6%), and 5.2% of patients with CMML (IDH1, 0.8%; IDH2, 4.4%). IDH mutations were enriched in subgroups with increased blasts but almost absent within MDS with biallelic TP53 inactivation. The comutational pattern differed by age, between MN, and between mutation hot spots. The underlying clonal hierarchy suggested that IDH mutations were present in the founder clone in many, but not all, patients. Finally, the high frequencies of IDH1 mutations in secondary AML and myelodysplasia-related AML (both 9.5%), compared with MDS (1.8%) and CMML (0.8%), indicate a frequent acquisition of this mutation at the transition to AML, which was directly confirmed in a subset of patients analyzed before and after progression. Overall, our findings have potential implications for sequential molecular testing and targeted treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019387","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:10:17Z","timestamp":1774015817000},"page":"3554-3564","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["<i>IDH1<\/i>\n                    - and\n                    <i>IDH2<\/i>\n                    -mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4441-9667","authenticated-orcid":false,"given":"Sandra","family":"Huber","sequence":"first","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Goessweiner","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"},{"name":"2Ludwig Maximilian University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-9838","authenticated-orcid":false,"given":"Wencke","family":"Walter","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isolde","family":"Summerer","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Ordemann","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pohlkamp","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7502-8243","authenticated-orcid":false,"given":"Niclas","family":"Kneisel","sequence":"additional","affiliation":[{"name":"3Servier Germany, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabit","family":"Delic","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-4380","authenticated-orcid":false,"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[{"name":"1MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"13","key":"2026052610372315600_bib1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/djq187","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism","volume":"102","author":"Reitman","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2026052610372315600_bib2","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/leu.2015.91","article-title":"Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms","volume":"29","author":"Molenaar","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"2026052610372315600_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2026052610372315600_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"2026052610372315600_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"2026052610372315600_bib6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41375-024-02246-2","article-title":"Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia","volume":"38","author":"Fruchtman","year":"2024","journal-title":"Leukemia"},{"issue":"6","key":"2026052610372315600_bib7","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1097\/HS9.0000000000000583","article-title":"Targeting IDH1 and IDH2 mutations in acute myeloid leukemia: emerging options and pending questions","volume":"5","author":"Wouters","year":"2021","journal-title":"Hemasphere"},{"issue":"16","key":"2026052610372315600_bib8","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026052610372315600_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2021-146932","article-title":"Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the idiome phase 2 study by the GFM group","volume":"138","author":"Sebert","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2026052610372315600_bib10","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome","volume":"8","author":"DiNardo","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026052610372315600_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-24-2196","article-title":"FDA approval summary: olutasidenib for adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 1 mutation","volume":"31","author":"Woods","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026052610372315600_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/17512433.2018.1477585","article-title":"Enasidenib for the treatment of acute myeloid leukemia","volume":"11","author":"Dugan","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"2026052610372315600_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2026052610372315600_bib14","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/cancers12092427","article-title":"Isocitrate dehydrogenase mutations in myelodysplastic syndromes and in acute myeloid leukemias","volume":"12","author":"Testa","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2026052610372315600_bib15","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026052610372315600_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"issue":"15","key":"2026052610372315600_bib17","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2003.99.091","article-title":"Morphologic dysplasia in acute myeloid leukemia: importance of granulocytic dysplasia","volume":"21","author":"Haferlach","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026052610372315600_bib18","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1182\/blood-2004-03-1036","article-title":"Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia","volume":"104","author":"Kern","year":"2004","journal-title":"Blood"},{"issue":"23","key":"2026052610372315600_bib19","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1182\/bloodadvances.2023011389","article-title":"The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing","volume":"7","author":"Maierhofer","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026052610372315600_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"4","key":"2026052610372315600_bib21","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/leu.2013.273","article-title":"The role of different genetic subtypes of CEBPA mutated AML","volume":"28","author":"Fasan","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2026052610372315600_bib22","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/leu.2011.97","article-title":"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia","volume":"25","author":"Schnittger","year":"2011","journal-title":"Leukemia"},{"issue":"16","key":"2026052610372315600_bib23","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2026052610372315600_bib24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"14","key":"2026052610372315600_bib25","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"2026052610372315600_bib26","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026052610372315600_bib27","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","article-title":"Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis","volume":"7","author":"Zarnegar-Lumley","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2026052610372315600_bib28","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.3390\/cancers14123012","article-title":"Prevalence and prognostic role of IDH mutations in acute myeloid leukemia: results of the GIMEMA AML1516 protocol","volume":"14","author":"Messina","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026052610372315600_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-023-00790-1","article-title":"Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome","volume":"13","author":"Eckardt","year":"2023","journal-title":"Blood Cancer J"},{"issue":"22","key":"2026052610372315600_bib30","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2026052610372315600_bib31","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","article-title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","author":"DiNardo","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2026052610372315600_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2026052610372315600_bib33","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3324\/haematol.2022.281607","article-title":"IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy","volume":"108","author":"Komrokji","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"2026052610372315600_bib34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41375-022-01551-y","article-title":"Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia","volume":"36","author":"Walsh","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026052610372315600_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/leu.2011.298","article-title":"Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients","volume":"26","author":"Patnaik","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2026052610372315600_bib36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41375-018-0299-2","article-title":"IDH1-R132 changes vary according to NPM1 and other mutations status in AML","volume":"33","author":"Falini","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2026052610372315600_bib37","doi-asserted-by":"crossref","first-page":"2180704","DOI":"10.1080\/16078454.2023.2180704","article-title":"Single-center, observational study of AML\/MDS-EB with IDH1\/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes","volume":"28","author":"Papadopoulou","year":"2023","journal-title":"Hematology"},{"issue":"2","key":"2026052610372315600_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ajh.23596","article-title":"IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution","volume":"89","author":"Lin","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"2026052610372315600_bib39","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","article-title":"Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: results from a large multicenter study","volume":"6","author":"Middeke","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026052610372315600_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-022-01339-8","article-title":"Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation","volume":"15","author":"Kunadt","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2026052610372315600_bib41","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41375-018-0026-z","article-title":"IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies","volume":"32","author":"Meggendorfer","year":"2018","journal-title":"Leukemia"},{"issue":"23","key":"2026052610372315600_bib42","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2026052610372315600_bib43","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026052610372315600_bib44","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41375-021-01368-1","article-title":"Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration","volume":"36","author":"Cappelli","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026052610372315600_bib45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2023-179737","article-title":"The frequency of clonal hematopoiesis prior to AML and MDS varies among the different molecularly defined who subtypes","volume":"142","author":"Baer","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026052610372315600_bib46","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41375-025-02851-9","article-title":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia \u2013 a HARMONY study","volume":"40","author":"Hern\u00e1ndez-S\u00e1nchez","year":"2026","journal-title":"Leukemia"},{"issue":"2","key":"2026052610372315600_bib47","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 update on menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol Rep"},{"issue":"suppl 1","key":"2026052610372315600_bib48","article-title":"Combination of menin and IDH mutant inhibition in acute myeloid leukemia","volume":"140","author":"Yoon","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026052610372315600_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2025","journal-title":"Blood"},{"issue":"19","key":"2026052610372315600_bib50","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/bloodadvances.2025016726","article-title":"Utility of IDH1\/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Boertjes","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026052610372315600_bib51","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.stem.2025.04.012","article-title":"Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia","volume":"32","author":"Sirenko","year":"2025","journal-title":"Cell Stem Cell"},{"issue":"26","key":"2026052610372315600_bib52","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2026052610372315600_bib53","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"issue":"2","key":"2026052610372315600_bib54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2643-3230.BCD-23-0195","article-title":"IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation","volume":"5","author":"Landberg","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026052610372315600_bib55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/leu.2015.129","article-title":"Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression","volume":"30","author":"Pellagatti","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2026052610372315600_bib56","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat Genet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3554\/2519588\/blooda_adv-2025-019387-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3554\/2519588\/blooda_adv-2025-019387-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:37:34Z","timestamp":1779806254000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3554\/567338\/IDH1-and-IDH2-mutated-myeloid-neoplasms-mutational"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019387","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,15]]}}}